Gland Pharma
Indian maker of sterile injectable generics and contract manufacturing, majority owned by China's Fosun.
On the record
Checkpoint: Resolution of Fosun's ~$3B stake sale to Blackstone/Brookfield/Warburg Pincus, plus FY27 Q1 results showing GLP-1 contract conversion
The call
Gland Pharma keeps growing on regulated manufacturing scale, with its next test being whether GLP-1 contracts convert to revenue and who ends up owning the company.
Gland Pharma manufactures sterile injectable medicines and makes custom drugs for big pharmaceutical clients. It is difficult to copy because building clean factories and earning FDA approval takes years, and it knows how to make complex formulas that others have not mastered yet. The main threats are not from artificial intelligence or new technology, but from two concrete things: first, Novo Nordisk and Eli Lilly are building their own factories to make GLP-1 drugs in-house instead of hiring Gland Pharma, which would shrink Gland Pharma's customer base; second, the company is in the middle of a ownership change (Fosun is selling its stake to a group of investment firms), and depending on who wins and what they decide, the company's direction could shift in unpredictable ways.
Why
01
AI pressure: None apparent. Sterile injectable manufacturing is a physical, regulated process; no AI tool currently replaces the plants, approvals, or sterility record needed to make these drugs. Could AI do the core job? Unlikely.
02
Bigger players: Novo Nordisk and Eli Lilly building in-house GLP-1 fill-finish capacity. Novo's Catalent buyout and Lilly's $27B US plant push could pull GLP-1 filling work in-house, capping the CDMO contracts Gland is counting on for FY27 growth. Could a giant copy it? No, they are blocked.
03
What protects it. FDA/EU sterile-injectable approvals and physical manufacturing capacity that take years, not quarters, for rivals to replicate.
What would change this call
Novo Nordisk or Eli Lilly announce fully in-house GLP-1 fill-finish capacity coming online. Would show big pharma insourcing GLP-1 manufacturing instead of using Gland as CDMO.
Gland's Fosun majority stake sale to Blackstone, Brookfield, or Warburg Pincus closes or collapses. Would show whether ownership change reshapes strategy or leadership within the company.
Gland's FY27 Q1/Q2 results show GLP-1 CDMO contracts converting to booked revenue as guided. Would show whether contracted GLP-1 pipeline is translating into actual sales growth.
Gland's Fosun majority stake sale to Blackstone, Brookfield, or Warburg Pincus closes or collapses. Would show whether ownership change reshapes strategy or leadership within the company.
Gland's FY27 Q1/Q2 results show GLP-1 CDMO contracts converting to booked revenue as guided. Would show whether contracted GLP-1 pipeline is translating into actual sales growth.
Key numbers
- FY26 revenue ₹6,430 crore, up ~14% YoY
- FY26 net profit ₹1,045 crore, up ~50% YoY
- CDMO revenue 46% of FY26 sales, growing 28% YoY
Named risks
- Unresolved Fosun majority-stake sale to Blackstone, Brookfield or Warburg Pincus creates governance uncertainty since Feb 2025.
- Novo Nordisk and Eli Lilly in-house GLP-1 buildout could cap upside if signed CDMO contracts fail to convert to FY27 revenue.
- Heavy US revenue concentration, over 75% of FY26 sales, exposes company to US tariff or pricing policy shifts.
- Cenexi integration still ramping, delayed synergy realization flagged by management as of May 2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Novo Nordisk / Eli Lilly | losing to | Building in-house GLP-1 fill-finish capacity, threatening Gland's CDMO contract conversion as of 2026-07 |
| Catalent (Novo Holdings owned) | gaining on | Novo-owned CDMO investing heavily in GLP-1 fill-finish capacity, competing for same contracts, 2026-04 |
| Stevanato Group | gaining on | Global CDMO expanding GLP-1 injectable capacity aggressively per 2026-03 industry reporting |
| Aurobindo Pharma, Sun Pharma, Dr. Reddy's Laboratories | contesting | Indian generic-injectable peers compared directly against Gland in FY26 financial listings |
Questions people ask
- Is Gland Pharma profitable in 2026?
- Yes. Gland Pharma reported FY26 (ended March 31, 2026) consolidated net profit of ₹1,045 crore, up about 50% YoY, on revenue of ₹6,430 crore, up roughly 14% YoY, per its May 2026 earnings release.
- Who owns Gland Pharma?
- Fosun Pharma remains the controlling shareholder, with its stake diluted to roughly 51.8% by December 2024. In February 2025, Blackstone, Brookfield and Warburg Pincus were reported in talks to buy Fosun's stake for about $3 billion, but the deal had not closed as of February 2026 filings.
- Could AI replace Gland Pharma?
- No. Gland Pharma's core business is FDA and EU regulated sterile injectable and fill-finish manufacturing, a physical, capital-intensive process protected by regulatory approvals and decades of complex-molecule know-how, none of which generative AI can substitute as of 2026.
- Who is Gland Pharma's biggest competitor threat?
- Novo Nordisk and Eli Lilly building in-house GLP-1 fill-finish capacity (including Novo's ownership of Catalent) pose the biggest structural risk to Gland's CDMO growth, while Aurobindo Pharma, Sun Pharma and Dr. Reddy's compete in generic injectables as of 2026.
- Is Gland Pharma laying off workers?
- No layoffs are reported. Company filings show full-time employee count rising to about 4,351 as of March 2025, up from 4,217 in 2024, alongside FY26 revenue growth of about 14% and profit growth of about 50%.
- What is Gland Pharma doing in GLP-1 manufacturing?
- Gland Pharma expanded GLP-1 fill-finish capacity from 40 million to 140 million units per year by end of 2025, launched its first partnered GLP-1 product (liraglutide) in 2025, and has signed eight GLP-1 CDMO contracts with more expected.
Timeline
- 2026-05-20Cenexi subsidiary confirmed EBITDA-positive, driving FY26 outlook commentary
- 2026-05-18Q4 FY26 results: revenue up 22% to ₹1,742.79 crore, profit up 97% to ₹366.7 crore, ₹20 dividend approved
- 2026-02-02Corporate profile still lists Gland Pharma as Fosun Pharma Industrial Pte Ltd subsidiary
- 2025-12GLP-1 fill-finish capacity reached 140 million units per year, up from 40 million
- 2025-02-19Blackstone, Brookfield, Warburg Pincus reported in talks to buy Fosun's stake for ~$3 billion
- 2025-02-12Reports say Fosun stake diluted to about 51.8% amid PE sale interest
- 2024-06Fosun stake reported diluted to about 58% via block deals
- 2023-04Acquisition of French CDMO Cenexi completed
- 2017Fosun Pharma acquired about 74% of Gland Pharma for $1.09 billion
Revision history
26 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Gland Pharma Reports 22% Revenue Surge to ₹1,742 Crore in Q4 FY26 (2026-05-18)
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY (2026-05-18)
- Gland Pharma Q4FY26 Press Release (2026-05-15)
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook (2026-05-20)
- GLAND Q4 2026 Earnings Call Highlights (2026-05-15)
- gurufocus.com (2026-07-26)
- GLAND Number of Employees (2026-07-17)
- Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billion (2026-06-19)
- Three global PE firms vie to buy Hyderabad's Gland Pharma from its Chinese owner (2025-02-12)
- Blackstone, Brookfield and Warburg Pincus in talks to acquire Gland Pharma's majority stake for $3 bn (2025-02-19)
- Gland Pharma: What Should You Do? (2026-07-14)
- Gland Pharma Limited (GLAND.BO) company profile and facts (2026-02-02)